Business
VALEO PHARMA CLOSES US$40 MILLION NON-DILUTIVE FINANCING FROM SAGARD HEALTHCARE PARTNERS
VALEO PHARMA CLOSES US$40 MILLION NON-DILUTIVE FINANCING FROM SAGARD HEALTHCARE PARTNERS.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nVALEO PHARMA CLOSES US$40 MILLION NON-DILUTIVE FINANCING FROM SAGARD HEALTHCARE PARTNERS\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nVALEO PHARMA CLOSES US$40 MILLION NON-DILUTIVE FINANCING FROM SAGARD HEALTHCARE PARTNERS\nCanada NewsWire\nMONTREAL, Aug. 2, 2022\n\n\n\nProceeds to fund acquisition of Canadian rights to 3 growing commercial stage drugsAcquisition allows Valeo to expand into Ophthalmology and Allergy    Licensing transactions to more than double Valeo's annual revenuesProvides financial flexibility to accelerate growth and reach profitability         MONTREAL, Aug. 2, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a growing Canadian pharmaceutical company, is pleased to announce that, it has closed a non-dilutive US$40 million Secured Term Loan (the \"Facility\") from Sagard Healthcare Partners.\n\n \n \n \n \n \n \n\n \nThe Facility is subject to the terms and conditions of a credit agreement. Highlights of the agreement are as follows:\nSenior secured term loan of up to US$40 million.        US$30 million fully funded on the closing.       Additional US$10 million available for future in-licensing transactions and/or acquisitions prior to December 31, 2023.          Facility matures after 5 years from closing.\"We are thrilled to have the financial support of Sagard Healthcare Partners, a sophisticated and knowledgeable healthcare investor. Their support is a testament to the quality of our commercial assets, the soundness of our business model and the talented team we have at Valeo\", said Steve Saviuk, CEO. \"This non-dilutive financing provides us with the necessary financial flexibility to accelerate our growth, deliver on defined value creation milestones and execute on our ambitious corporate objectives.\"\n\"We are excited to support Valeo as it continues to build a broad portfolio of comme...